Global Proteomics Market

  • May 2014
  • -
  • Global Industry Analysts
  • -
  • 234 pages

This report analyzes the worldwide markets for Proteomics in US$ Million. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2013 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 82 companies including many key and niche players such as -

ActivX Biosciences, Inc.
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Bruker Daltonics, Inc.
Caprion Proteomics, Inc.

Table Of Contents




I. INTRODUCTION, METHODOLOGY and PRODUCT DEFINITIONS
Study Reliability and Reporting Limitations I-1
Disclaimers I-2
Data Interpretation and Reporting Level I-2
Quantitative Techniques and Analytics I-3
Product Definitions and Scope of Study I-3


II. EXECUTIVE SUMMARY

1. GLOBAL MARKET OVERVIEW II-1
Proteomics - The Current Spotlight II-1
Proteomics: A Critical Drug Discovery Tool II-2
Research to Dominate the Market in the Immediate Future II-3
Proteomics Technologies: Growing in Significance II-3
New Developments in Proteomics Technologies II-4
Market Drivers/Trends/Challenges II-5
Personalized Medicine Slowly Gaining Ground II-5
Table 1: Drug Ineffectiveness for Select Therapeutic
Categories as a Percentage of Patient Population (includes
corresponding Graph/Chart) II-5

Table 2: Global Population Statistics for the 65+ Age Group
(2012) (includes corresponding Graph/Chart) II-7

Table 3: Percentage of Population Aged 65 and Above in
Europe, US, and Japan (1960-2030) (includes corresponding
Graph/Chart) II-8

Table 4: Elderly Population (65+ Years) as a Percentage of
the Total Population: 2025 (includes corresponding
Graph/Chart) II-8
Advancements in Proteomics Bring Biomarkers into Limelight II-8
List of US-FDA Approved Biomarkers for Cancer II-9
Oncology - A Key Focus Area for Proteomics II-10
Table 5: World Cancer Incidence by Geographic Region and
Gender (2012): Number of New Cancer Cases Reported (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America and The Caribbean, and Africa (includes corresponding
Graph/Chart) II-11

Table 6: New Cancer Cases in the World by Affected Site
(2012) (in Thousands) (includes corresponding Graph/Chart) II-12

Table 7: Cancer Incidence in Developed Nations by Site: 2012
(includes corresponding Graph/Chart) II-13

Table 8: Global Incidence of Common Cancers in Men (2012):
Number of New Cases Reported in Thousands for Lung and
Bronchus, Prostate, Colorectal, and Liver Cancers (includes
corresponding Graph/Chart) II-14

Table 9: Global Incidence of Common Cancers in Women (2012):
Number of New Cases Reported in Thousands for Breast,
Colorectal, Lung and Bronchus, and Liver Cancers (includes
corresponding Graph/Chart) II-14

Table 10: World Cancer Mortality by Geographic Region and
Gender (2012): Number of Cancer- Related Deaths (in
Thousands) for Asia-Oceania, Europe, North America, Latin
America and The Caribbean, and Africa (includes corresponding
Graph/Chart) II-15
International Initiatives in the Proteomics Market II-15
China All Set To Play a Major Role in the Proteomics Industry II-16
Global Proteomics Sample Preparation Market - On a Growth Curve II-16
Challenges Facing Proteomics Sample Preparation Market II-17
Industrialization of Proteomics Research Propels Sample
Preparation Technologies II-17
Factors Limiting Market Growth II-17
Impact of the Economic Recession on the Life Sciences Industry
in Retrospect II-17
Challenges Facing Proteomics Industry II-18
Protein Chemistry and its Complexities II-18
Quantitation II-18
Integration of Data and Equipment II-18
Data Validation - A Burning Issue II-19
Standardization and Consistency - A Prime Concern II-19
Incomplete and Disorganized Data II-19

2. INDUSTRY COMPETITION II-20
A Highly Fragmented Market II-20
Tool Providers: Leading the Proteomics Market II-21
Role of Contract Research Organizations - All Set to Increase
in Proteomics II-21

3. PRODUCT AND TECHNOLOGY OVERVIEW II-22
Proteins, Proteome and Proteomics!!! - What are they? II-22
Proteomics - An Introduction II-22
Genesis of Proteomics II-23
Components of Proteomics II-24
Expression Proteomics II-24
Functional Proteomics II-24
Cell-map Proteomics II-24
Structural Proteomics II-24
Technologies and Proteomics II-24
Proteomics and Genomics II-25
Proteomics and Genomics: A Comparison II-25
Protein Production Pathway: From Gene Expression to
Functional Protein with Controls II-25
From Genomics to Proteomics II-26
Functional Genomics and Proteomics II-26
Push from Genomic Information II-27
An Insight into Proteomics Data Type and their
Characteristics / Features II-27
Standard Proteomics Approach II-27
Sample Preparation - Step I II-28
Protein Separation - Step II II-28
Protein Visualization II-28
Protein Expression Analysis-Step III II-28
Image Analysis - Identify differentially expressed spots II-28
Protein Identification - Step IV II-29
Data Storage and Processing - Step V II-29

4. OVERVIEW OF PROTEOMICS TECHNOLOGIES II-30
A Snapshot of Various Proteomics Tools II-30
An Insight into Various Proteomics Technologies and their
Application Areas II-30
Protein Separation II-30
2-Dimensional Gel Electrophoresis (2DGE) II-31
Elements of 2-DE Proteomics II-31
Two -Dimensional Differential Gel Electrophoresis II-31
Combining 2D Gel Electrophoresis with Mass Spectrometry (MS) II-31
2D Capillary LC II-32
Analytical Strength of LC-MS and MS/MS in Shotgun Protein
Sequencing II-32
Protein Characterization II-32
Analysis of Protein through Mass Spectrometry II-32
MS and Proteins II-32
Comparison of MS Techniques II-33
Applications of MS II-33
Problems Associated with MS II-34
Types of Analyzers or Filters II-34
MALDI-TOF MS II-34
MS/MS II-34
SELDI-TOF II-34
Laser Capture Microdissection II-35
Tandem MS II-35
Y2H, Yeast 2-Hybrid System II-35
Sensitivity of Two-Hybrid Assays II-35
Limitations of Y2H II-36
Protein Microarrays II-36
Market Influencers in Protein Microarrays Market II-36
Chip Technology II-36
Microfluidic Applications II-37
Role of Bioinformatics in Proteomics II-37
Bioinformatics Applications and Tools in Proteomics II-37
MS Programs II-37
2- DE gel Comparison II-38
2-DE Databases II-38
Databases of 2D-electrophoretic maps II-38
Emerging Proteomics Technologies II-39
MudPIT II-39
ICAT II-39
ICAT strategy: A solution to quantitative proteome analysis II-39
Phage Display Technique II-39
Advanced Proteomics Technologies: Structural Analysis Tools II-40
X-ray Crystallography II-40
Nuclear Magnetic Resonance (NMR) II-40
In silico Modelling II-40
Physicochemical Factors Constraining Metabolic Functions II-41

5. END-USE APPLICATION AREAS II-42
Proteomics in Drug Discovery and Diagnostics II-43
Proteomics and Drug Discovery II-43
Protein Microarrays: A New Tool for the Development of
Pharmaceuticals II-44
Proteomic Approaches Gain Prominence in Cancer Drug Discovery II-44
Proteomics Technologies Used in Cancer Drug Discovery and
Development II-45

6. NEW PRODUCT LAUNCHES/DEVELOPMENTS II-46
Proteome Sciences Validates Novel Protein Biomarkers II-46
KineMed to Apply Its MS Proteomics Platform to Study
Neurodegeneration II-46
Agilent and MRM Proteomics Introduce PeptiQuant Kits for High
-Quality Plasma Proteomic Analysis II-46
Elsevier Launches ‘Translational Proteomics’ Open-Access Journal II-46
Applied Biomics Introduces Global Protein Post- Translational
Modification Profiling Service II-46
AB SCIEX Launches New Column Chips II-47
Applied Biomics Introduces New Mass Spectrometry Service II-48
Norton Scientific Introduces Novel Specialist Applications
Development Laboratory Service II-48
Gentel Biosciences Introduces APiXâ„¢ Disease Profiling Kit II-48
Integromics Introduces OmicsHub Proteomics 2.0 II-49
Bruker Introduces amaZon Speed Ion Trap Mass Spectrometers II-49
Applied Biomics Introduces iTRAQ Service for Proteomics Research II-50
Norton Scientifc Introduces New Lab Support Service for Rapid
RNA/DNA and Protein Measurement II-50
Bruker Launches MALDI Biotargetâ„¢ II-51
Thermo Fisher Launches UHLPC System II-51
Kinexus Introduces Human Gene Online TranscriptoNET KnowledgeBase II-52
Bruker Launches PRIME Integrated Proteomics Solution II-52
Applied Biosystems Launches LS*LIMS Laboratory Automation
Technology for Proteomics and Genomics II-53
Kinexus Bioinformatics Introduces Online KiNET-AM Proteomics
DataBase II-53
Bruker Rolls Out CaptiveSpray Electrospray Ion Source for
Proteomics Applications II-54
Thermo Fisher Launches New Capabilities for Performing
Proteomics Workflows II-54
National Cancer Institute Introduces Clinical Proteomic Tumor
Analysis Consortium for Cancer Studies II-55
KinaSorbâ„¢ - New Kit for Kinase Enrichment II-55

7. RECENT INDUSTRY ACTIVITY II-56
Retroscreen Virology Group Acquires Activiomics II-56
Thermo Fisher Scientific Acquires Life Technologies Corporation II-56
Fluidigm Corporation Buys DVS Sciences II-56
Geneva Bioinformatics Collaborates with University of Washington II-56
Applied Proteomics Partners with German Research Institute II-56
Agilent Technologies Enters Agreement with SomaLogic II-57
Biognosys Partners with CellnTEC II-57
Proteome Sciences Enters Contract with Thermo Fisher Scientific II-57
Agilent Technologies Partners with Sera Prognostics II-57
Chicago Growth Partners Buys Caprion Proteomics from Thallion II-57
GlaxoSmithKline Fully Acquires Cellzome II-58
Proteome Sciences Signs Agreement with CHDI Foundation II-58
Waters Corp. Inks Agreement with Nonlinear Dynamics II-58
BioFocus Enters into Alliance with Activiomics II-58
Great Point Partners Divests Caprion Proteomics II-59
Glaxo Smith Kline Takes over Cellzome II-59
Emerald BioSystems Changes Name to Emerald Bio II-59
Bruker Unveils Novel Nano-Advance UHPLC System II-60
Evotec Takes Over Kinaxo Biotechnologies II-60
Kinaxo Biotechnologies and AstraZeneca Sign Agreement II-60
Gentel Biosciences Takes over Eppendorf’s SilverQuant Trademark II-60
Thermo Fisher Takes Over Fermentas International II-61
KINAXO to Collaborate with Takeda II-61
Dualsystems and Bulldog Bio Signs Exclusive Marketing Agreement II-61
Novartis Enters into Agreement with SomaLogic II-62
Sage-N Inks Exclusive Pact with the U.S. Army II-62
Proteome Sciences Inks Agreement with Moffitt Cancer Center II-62
Gentel Biosciences Enters into Agreement with Oregon Health and
Science University II-62
Evotec OAI Forms Joint Venture with MeITec to Collaborate on
Drug Discovery Services II-63

8. FOCUS ON SELECT KEY PLAYERS II-64
ActivX Biosciences, Inc. II-64
Agilent Technologies, Inc. II-64
Bio-Rad Laboratories, Inc. II-64
Bruker Daltonics, Inc. II-65
Caprion Proteomics, Inc. II-66
Digilab Genomic Solutions, Inc. II-66
GE Healthcare II-67
Geneva Bioinformatics S.A. II-67
Hybrigenics SA II-68
EMD Millipore/Merck Millipore Corp. II-68
PerkinElmer, Inc. II-68
Shimadzu Corporation II-69
Sigma-Aldrich Corporation II-69
Thermo Fisher Scientific II-70
Waters Corp. II-70
Xencor Inc. II-71

9. GLOBAL MARKET PERSPECTIVE II-72
Table 11: World Recent Past, Current and Future Analysis for
Proteomics by Geographic Region - US, Canada, Japan, Europe,
Asia-Pacific, Latin America, and Rest of World Markets
Independently Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) II-72

Table 12: World Historic Review for Proteomics by Geographic
Region - US, Canada, Japan, Europe, Asia-Pacific, Latin
America, and Rest of World Markets Independently Analyzed with
Annual Sales Figures in US$ Million for Years 2006 through
2012 (includes corresponding Graph/Chart) II-73

Table 13: World 15-Year Perspective for Proteomics by
Geographic Region - Percentage Breakdown of Dollar Sales for
US, Canada, Japan, Europe, Asia-Pacific, Latin America, and
Rest of World Markets for Years 2006, 2014 and 2020 (includes
corresponding Graph/Chart) II-74


III. MARKET

1. THE UNITED STATES III-1
A.Market Analysis III-1
Current and Future Analysis III-1
Personalized Medicine - A Major Driver for the Proteomics
Market III-1
Table 14: US Market for Hospital Cancer Therapies by
Treatment Type (2004 and 2010): Percentage Breakdown of
Revenues for Surgery, Chemotherapy Drugs, Radiation
Therapy, Biotechnology-Based Drugs, and Others (includes
corresponding Graph/Chart) III-2
Cancer Presumes Epidemic Proportion in the US III-2
Table 15: New Cancer Cases by Gender and Affected Site in
the US (2013) III-3
Proteomics to Provide POCT for Patients in Hospice Care III-4
Leading Market for Rapid and Automated Microbiological Tests III-4
Demographic Changes Offer Growth Opportunities III-5
Table 16: North American Aging Population by Age Group:
1975-2050 (includes corresponding Graph/Chart) III-5
Proteomics Sample Preparation Market III-6
FDA’s Antidote III-6
New Product Launches III-6
Strategic Corporate Developments III-12
Key Players III-18
B.Market Analytics III-24
Table 17: The US Recent Past, Current and Future Analysis for
Proteomics Market Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-24

Table 18: The US Historic Review for Proteomics Market
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-25

2. CANADA III-26
A.Market Analysis III-26
Rising Incidence of Chronic Diseases Spurs Proteomics Demand III-26
Table 19: New Cancer Cases in Canada by Gender and Affected
Site (2012) (includes corresponding Graph/Chart) III-27

Table 20: New Cancer Cases in Canada by Province (2012)
(includes corresponding Graph/Chart) III-28

Table 21: New Cancer Cases in Canada by Age Group and
Gender (2012) (includes corresponding Graph/Chart) III-29
New Product Developments III-30
Strategic Corporate Development III-31
Caprion proteomics, Inc. - A Key Player III-31
B.Market Analytics III-32
Table 22: Canadian Recent Past, Current and Future Analysis
for Proteomics Market Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-32

Table 23: Canadian Historic Review for Proteomics Market
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-33

3. JAPAN III-34
A.Market Analysis III-34
Demographics Drive Market Growth III-34
Table 24: Percentage Breakdown of Japanese Population by
Age Group (2012) (includes corresponding Graph/Chart) III-34
Table 25: Over 65 Years Population in Japan (1950-2010)
(includes corresponding Graph/Chart) III-35
Shimadzu Corp. - A Key Player III-35
B.Market Analytics III-36
Table 26: Japanese Recent Past, Current and Future Analysis
for Proteomics Market Analyzed with Annual Sales Figures in
US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-36

Table 27: Japanese Historic Review for Proteomics Market
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-37

4. EUROPE III-38
A.Market Analysis III-38
Debt Crisis in Europe Affects Healthcare Industry III-38
European Healthcare System: In a State of Transition? III-38
Cancer Trends III-38
Table 28: Cancer Incidence in Europe by Site: 2012 (in
Thousands) (includes corresponding Graph/Chart) III-39
Aging Population to Drive Demand for Proteomics III-40
Table 29: Population Breakup by Age Group for Select
European Countries: 2012 (As a % of Total Population)
(includes corresponding Graph/Chart) III-40
European Personalized Medicine Market to Exhibit Robust Growth III-41
Proteomics Market in Europe III-41
Table 30: European Proteomics Market (2013): Percentage
Breakdown of Deployment of Proteomics Technologies in
End-Use Segment - Research and Academic Institutions,
Pharmaceutical Companies, and Clinical Laboratories
(includes corresponding Graph/Chart) III-41
Proteomics Research in Europe - An Overview III-41
Protein Identification Market III-42
Protein Separation Market III-43
Market Challenges III-43
Gaining Edge in the Proteomics Industry - Player Strategies III-43
European 2DE Market - Benefiting from Recession III-44
New Product Developments III-44
Strategic Corporate Developments III-45
Select Key Players III-47
B.Market Analytics III-49
Table 31: European Recent Past, Current and Future Analysis
for Proteomics by Geographic Region - France, Germany,
Italy, UK and Rest of Europe Markets Independently Analyzed
with Annual Sales Figures in US$ Million for Years 2013
through 2020 (includes corresponding Graph/Chart) III-49

Table 32: European Historic Review for Proteomics by
Geographic Region - France, Germany, Italy, UK and Rest of
Europe Markets Independently Analyzed with Annual Sales
Figures in US$ Million for Years 2006 through 2012 (includes
corresponding Graph/Chart) III-50

Table 33: European 15-Year Perspective for Proteomics by
Geographic Region - Percentage Breakdown of Dollar Sales for
France, Germany, Italy, UK and Rest of Europe Markets for
Years 2006, 2014 and 2020 (includes corresponding
Graph/Chart) III-51

4a. FRANCE III-52
A.Market Analysis III-52
French Proteomics Player - Hybrigenics Sa III-52
B.Market Analytics III-53
Table 34: French Recent Past, Current and Future Analysis for
Proteomics Market Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-53

Table 35: French Historic Review for Proteomics Market
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-54

4b. GERMANY III-55
Market Analysis III-55
Table 36: German Recent Past, Current and Future Analysis for
Proteomics Market Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-55

Table 37: German Historic Review for Proteomics Market
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-56

4c. ITALY III-57
Market Analysis III-57
Table 38: Italian Recent Past, Current and Future Analysis for
Proteomics Market Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-57

Table 39: Italian Historic Review for Proteomics Market
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-58

4d. THE UNITED KINGDOM III-59
A.Market Analysis III-59
Highlights III-59
Increased Support for Personalized Medicine to Drive
Proteomics Demand III-59
Strategic Corporate Development III-59
Key Player - Ge Healthcare III-60
B.Market Analytics III-61
Table 40: The UK Recent Past, Current and Future Analysis for
Proteomics Market Analyzed with Annual Sales Figures in US$
Million for Years 2013 through 2020 (includes corresponding
Graph/Chart) III-61

Table 41: The UK Historic Review for Proteomics Market
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-62

4e. REST OF EUROPE III-63
A.Market Analysis III-63
Key Swiss Player - Geneva Bioinformatics S.A. III-63
B.Market Analytics III-63
Table 42: Rest of European Recent Past, Current and Future
Analysis for Proteomics Market Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-63

Table 43: Rest of European Historic Review for Proteomics
Market Analyzed with Annual Sales Figures in US$ Million for
Years 2006 through 2012 (includes corresponding Graph/Chart) III-64

5. ASIA-PACIFIC III-65
A.Market Analysis III-65
Healthcare Spending in Asia-Pacific: On the Rise III-65
China III-65
Table 44: China - The Most Populous Country Worldwide (July
2013): Total Population (in Millions) by Age Group 0-14
Years, 15-44 Years, 45-64 Years, and 65+ Years for China
Vis-a-Vis Other Countries (includes corresponding
Graph/Chart) III-66

Table 45: China - The Most Populous Country Worldwide (July
2013): Percentage Population by Age Group 0-14 Years, 15-44
Years, 45-64 Years, and 65+ Years for China Vis-a-Vis Other
Countries (includes corresponding Graph/Chart) III-67
Government Support Drives Personalized Medicine Market in China III-67
Australia III-68
India III-68
Indian Scientific Research towards Functional Genomics and
Proteomics III-68
B.Market Analytics III-69
Table 46: Asia-Pacific Recent Past, Current and Future
Analysis for Proteomics Market Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-69

Table 47: Asia-Pacific Historic Review for Proteomics Market
Analyzed with Annual Sales Figures in US$ Million for Years
2006 through 2012 (includes corresponding Graph/Chart) III-70

6. LATIN AMERICA III-71
Market Analysis III-71
Table 48: Latin American Recent Past, Current and Future
Analysis for Proteomics Market Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-71

Table 49: Latin American Historic Review for Proteomics
Market Analyzed with Annual Sales Figures in US$ Million for
Years 2006 through 2012 (includes corresponding Graph/Chart) III-72

7. REST OF WORLD III-73
Market Analysis III-73
Table 50: Rest of World Recent Past, Current and Future
Analysis for Proteomics Market Analyzed with Annual Sales
Figures in US$ Million for Years 2013 through 2020 (includes
corresponding Graph/Chart) III-73

Table 51: Rest of World Historic Review for Proteomics
Market Analyzed with Annual Sales Figures in US$ Million for
Years 2006 through 2012 (includes corresponding Graph/Chart) III-74


IV. COMPETITIVE LANDSCAPE

Total Companies Profiled: 82 (including Divisions/Subsidiaries - 85)

The United States (54)
Canada (4)
Japan (2)
Europe (24)
- France (3)
- Germany (6)
- The United Kingdom (7)
- Spain (1)
- Rest of Europe (7)
Asia-Pacific (Excluding Japan) (1)

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Regulatory Affairs Outsourcing Market (Services: Regulatory Affairs, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation and Others) - Global Industry Analysis, Size, Sha

Regulatory Affairs Outsourcing Market (Services: Regulatory Affairs, Clinical Trial Applications and Product Registrations, Regulatory Writing and Publishing, Regulatory Consulting and Legal Representation and Others) - Global Industry Analysis, Size, Sha

  • $ 4 795
  • Industry report
  • October 2014
  • by Transparency Market Research

This report on the regulatory affairs outsourcing market studies the current as well as future prospects of the market globally. Regulatory affairs outsourcing is rapidly gaining popularity in the global ...

Proteomics Markets for Research and IVD Applications

Proteomics Markets for Research and IVD Applications

  • $ 4 200
  • Industry report
  • September 2014
  • by Kalorama Information

This Kalorama Information report defines markets and identifies trends for proteomics applications, both in their research use and in IVD. Proteomics is the study of proteins, including the study of the ...

Biologicals in Oncology Drug Pipeline Update 2014

Biologicals in Oncology Drug Pipeline Update 2014

  • $ 3 749
  • Industry report
  • October 2014
  • by Bioseeker

This drug pipeline update covers a wide array of biological drugs, such as: antibodies,proteins, peptides, DNA, RNA and cellular therapies. There are today 908 companies plus partners developing 1784 biological ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.